Cargando…

Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients

OBJECTIVE: Germline alterations in the breast cancer susceptibility genes type 1 and 2, BRCA1 and BRCA2, predispose individuals to hereditary cancers, including breast, ovarian, prostate, pancreatic, and stomach cancers. Accumulating evidence suggests inherited genetic susceptibility to lung cancer....

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xingsheng, Yang, Dongyong, Li, Yalun, Li, Li, Wang, Yan, Chen, Peng, Xu, Song, Pu, Xingxiang, Zhu, Wei, Deng, Pengbo, Ye, Junyi, Zhang, Hanhan, Lizaso, Analyn, Liu, Hao, Mao, Xinru, Huang, Hai, Chu, Qian, Hu, Chengping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chinese Anti-Cancer Association 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6743617/ https://www.ncbi.nlm.nih.gov/pubmed/31565484 http://dx.doi.org/10.20892/j.issn.2095-3941.2018.0506

Ejemplares similares

Erratum to Prevalence and clinical significance of pathogenic germline BRCA1/2 mutations in Chinese non-small cell lung cancer patients
por: Hu, Xingsheng, et al.
Publicado: (2020)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Novel AMBRA1-ALK fusion identified by next-generation sequencing in advanced gallbladder cancer responds to crizotinib: a case report
por: Zhou, Yuling, et al.
Publicado: (2020)

Rechallenge with erlotinib in osimertinib-resistant lung adenocarcinoma mediated by driver gene loss: a case report
por: Liu, Lingli, et al.
Publicado: (2020)

The prognostic value of longitudinal circulating tumor DNA profiling during osimertinib treatment
por: Ma, Shenglin, et al.
Publicado: (2021)

The utility of sputum supernatant as an alternative liquid biopsy specimen for next-generation sequencing-based somatic variation profiling
por: Qin, Ling, et al.
Publicado: (2022)

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer
por: Zeng, Liang, et al.
Publicado: (2020)

Clinical characteristics and prognostic significance of 92 cases of patients with primary mixed-histology lung cancer
por: DENG, PENGBO, et al.
Publicado: (2013)

The emergence of various genetic alterations mediated the Osimertinib resistance of a patient harboring heterozygous germline EGFR T790M: a case report
por: Liu, Bin, et al.
Publicado: (2021)

Management Strategies of Breast Cancer Patients with BRCA1 and BRCA2 Pathogenic Germline Variants
por: Edaily, Sarah, et al.
Publicado: (2022)

High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy
por: Wu, Shibo, et al.
Publicado: (2020)

Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients
por: Deng, Hongyu, et al.
Publicado: (2019)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Kitahara, Miyuki, et al.
Publicado: (2021)

Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2
por: Bernstein-Molho, Rinat, et al.
Publicado: (2022)

Investigation on the potential of circulating tumor DNA methylation patterns as prognostic biomarkers for lung squamous cell carcinoma
por: Liu, Yutao, et al.
Publicado: (2020)

Pathogenic Germline BRCA1/2 Mutations and Familial Predisposition to Gastric Cancer
por: Ichikawa, Hiroshi, et al.
Publicado: (2018)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

The utilization of next-generation sequencing to detect somatic mutations and predict clinical prognosis of Chinese non-small cell lung cancer patients
por: Cao, Liming, et al.
Publicado: (2018)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer
por: Viansone, A., et al.
Publicado: (2022)

Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers
por: Lee, Young-Jae, et al.
Publicado: (2017)

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
por: Maxwell, Kara N., et al.
Publicado: (2017)

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants
por: Lambertini, Matteo, et al.
Publicado: (2021)

Impact of Breast Cancer and Germline BRCA Pathogenic Variants on Fertility Preservation in Young Women
por: Prokurotaite, Elze, et al.
Publicado: (2023)

Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants
por: Dias, Alexander, et al.
Publicado: (2023)

Concurrent germline BRCA1, BRCA2, and CHEK2 pathogenic variants in hereditary breast cancer: a case series
por: Sukumar, Jasmine, et al.
Publicado: (2021)

COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore
por: Zhang, Zewen, et al.
Publicado: (2023)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Germline mutations in 5’ to c.7914 of BRCA2 significantly increase risk of prostate cancer
por: Ruan, Xiao-Hao, et al.
Publicado: (2022)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer
por: Muranen, Taru A., et al.
Publicado: (2020)

Reproductive issues in carriers of germline pathogenic variants in the BRCA1/2 genes: an expert meeting
por: Buonomo, Barbara, et al.
Publicado: (2021)

A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma
por: Correa, Tatiana, et al.
Publicado: (2020)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

The occurrence of germline BRCA1 and BRCA2 sequence alterations in Slovenian population
por: Stegel, Vida, et al.
Publicado: (2011)

MicroRNA-223 Promotes Tumor Progression in Lung Cancer A549 Cells via Activation of the NF-κB Signaling Pathway
por: Huang, Li, et al.
Publicado: (2016)

Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
por: Zhang, Yunuo, et al.
Publicado: (2022)

Erratum: Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
Publicado: (2022)

Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature
por: Hu-Heimgartner, Ketty, et al.
Publicado: (2023)

Age-dependent penetrance of different germline mutations in the BRCA1 gene
por: Al-Mulla, F, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_us1e4rj3km0gtab660c71vnh7b